Indian Journal of Biochemistry & Biophysics
Vol. 46, February 2009, pp. 31-36

Minireview

Future Perspectives of Nutrigenomics Foods: Benefits vs. Risks
Dilip Ghosh*
Smart Foods Centre, University of Wollongong, NSW 2522, Australia
Received 20 September 2008; revised 10 November 2008
Nutrigenomics, defined as the application of high-throughput genomics tools in nutrition research is now past its
incubation phase. The poorly understood associations of diet and disease prevention in particular will likely be the single
most important catalyst to its accelerated and continued growth. Whether the goal of matching foods to individual genotypes
to improve the health of those individuals can be attained, and personalised nutrigenomic foods enter the world's food
markets, depends on numerous hurdles being overcome: some scientific in nature, some technical and others related to
consumer, market or ethical issues. Public adoption of new technologies is an important determinant for their success. Many
of the drivers behind the trend in personalisation of food are now known, particularly ethical, legal, and social issues (ELSI)
are the major drivers. Future development in the field of nutrigenomics undoubtedly will place its seemingly huge potential
in better perspective. From the scientific responsibility point of view, one hopes that the new perspectives to be gained and
progress to be made in this field will be so managed as to take the public at large on board, if we are to avoid another
nutrition education disaster of the genetically modified organism type and dimension.
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Introduction
Fifty-four years ago, Watson and Crick described
DNA as a double-helix structure. The publication of
the human genome in 2001 represented a
revolutionary breakthrough in health and nutrition
research and its market applications. Both nutrients
and non-nutrient components of foods, diets and
lifestyle can affect every step in the flow of genetic
information from gene expression to protein synthesis
level. This transition may alter metabolic function of
our body in a very complex ways. Like the
pharmaceutical industry, the food industry now has an
opportunity to position food and nutritional bioactives
to promote health and prevent disease based on
knowledge of the genetic make-up of individual
consumers1.
The new paradigm for the interplay between the
human genome and its environment is the genomefood interactions. “Nutrition and food science are
stepping into the genomic era, and it is becoming
evident that nutrients and other food components are
key factors in altering gene transcription, protein
levels and functions and the metabolome, which
eventually translates into a health or disease state on
the basis of a given genome”2. Thus, the
——————
*E-mail: dilip.ghosh@bigpond.com
Ph: 61-2-4221 5769; Fax: 61-2-4221 4844

nutrigenomics/nutrigenetics is an approach to
nutrition and human health that takes into account and
studies the effect of genetic differences in human
responses to foods. Nutrigenomics is emerging at the
same time as the functional food industry, a
movement that is working toward foods that provide
benefits beyond basic nutrition3.
Nutrigenomics is an emerging science with high
consumer expectations, but the major concerns are
whether the goal of matching foods to individual
genotypes to improve the health of those individuals
can be attained, and personalised nutrigenomic foods
enter the world's food markets, depends on numerous
hurdles being overcome: some scientific in nature,
some technical and others related to consumer, market
or ethical issues.
In this review, emerging paradigms of nutritional
genomics are discussed as they relate to the functional
food market. Emphasis is given on how genomics
tools can be leveraged to produce better food to
improve human nutrition and health and thereby
deliver societal and economic benefits.
Pharmacogenomics vs Nutrigenomics
The boundary between the health effects and foods
is becoming blurred everyday with the development
of the concept of personalised functional food. The
terms pharmacogenomics and nutrigenomics both
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have grown out at their genetic ancestors as large
scale “-omics” technologies and can be used to
individualise or personalise medicine or food. But,
unlike pharmaceutical, food consumption does not
deal with ‘single exposure-single time point’ effects,
but the multiple dosing of complex mixtures of
bioactive compounds, mostly at the low doses. It is
very hard to detect all biological effects of a food
component, food or diet. Thus, it is advisable to start
with food components that are well characterized in
terms of their metabolism, the cellular processes and
health outcomes. The rapid advancement of analytical
tools
in
transcriptomics,
proteomics
and
metabolomics will enable not only increased detection
sensitivity, but a greater range of effects. Thus,
multiple minor changes taken together can be exposed
with new bioinformatics approaches created with a
broader sensitivity.
Drivers in functional foods
There are a number of drivers for functional foods,
with trends emerging in market analyses. New
Nutrition Business, for example, publishes “10 Key
Trends in Functional Foods” on a regular basis4.
Although ‘nutrigenomic’ foods have yet to be
mentioned specifically as such, many of the 2008
trends described in the marketing sense refer directly
or indirectly to “personalisation” aspects. One recent
market analysis on functional foods5 noted that
although the industry is already crowded, there
appears to be some splintering into subcategories
based on consumer target markets (niche markets).
Many of the drivers behind this trend in
personalisation of food are changing demographics
and social trends (more “singles” and childless
couples), consumers awareness and subsequently
increased scientific research-led clinical evidence for
the efficacy of functional foods, increased nutritionoriented marketing activity, particularly targeting
health professionals, and the penetration of mass
market distribution channels6. The consumer’s
preference for optimal health is an also a major driver
for food choice and food production” 7. Ethical legal
and social issues are adding a new dimension in
functionalised food development as a future driver.
Applications
Food is central to health, and advice on food
consumption patterns is an important component of
health promotion and the management of lifestyle

related diseases such as obesity, heart disease and
type-2 diabetes mellitus8. We are now able to better
appreciate that not only do foods deliver nutrients and
other bioactive components, they also deliver them in
an interactive matrix within single foods and then in
whole diets.
Thus, while foods deliver nutrients that interact
with genetic potential, not everyone is the same.
While it may seem that there is enough similarity
within populations to show effects of diet, there is a
need to individualise advice, if we want to assure that
the dietary strategy will benefit everyone. In addition,
it must be remembered that people eat foods, not
single nutrients in the diet and it is still this
combination of food components that will have the
ultimate effect. While there is a lot known about
dietary fat and its effects on risk factors for chronic
lifestyle related disease, there are numerous other
food components that have implications for disease
pathology. Put together, from a practice perspective,
Ordovas9 argues that there is not enough information
to begin personalised nutrition on a grand scale just
yet, but there is evidence of proof of concept in the
case of dietary fat and lipid metabolism. The dietary
polyunsaturated fatty acid (PUFA), for example is
positively implicated in the management of risk
factors and we can provide advice on useful whole
diet models that assure a good balance of these fatty
acids from targeted foods10,11. We can also prescribe
foods that contain bioactives known to be beneficial12.
In this manner, personalised advice takes the form of
specific food-based advice that can be ultimately
refined, as more knowledge on the nutrigenomics
interface comes to hand.
Beyond agricultural application, the introduction of
genomic technologies are now promising in food
processing, food safety and quality assurance. In food
processing, a relatively new application of these
technologies is the discovery of ‘process markers’ to
guide industrial processes or improve supply chain
management. This application is very successful in
tea manufacturing complex process and management
of post-harvesting yellowing and short-life of
broccoli13. The safety evaluation of food
components14 and the detection and identification of
microorganisms during food spoilage15 are the major
applications in food safety area. DNA finger printing
is now being widely applied within the food industry
as a means of authenticating plants, animals and
packaged food products16.
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Food outcomes and attributes
The modern technologies at the molecular level
have proven the scientific concept what Hippocrates
uttered, “let food be your medicine and medicine your
food” in 390 BC. There are indications from initial
consumer’s studies that US consumers will accept
functional foods based on nutrigenomic principles.
Designed to address various health issues, these foods
are likely to enter into consumer market over the next
few decades17. Two kinds of food outcomes are
thought to emerge from research in the nutrigenomics
area. Firstly, foods will result from “public good”
information. This information will identify food
components that are relevant to the needs of people
with specific genetic conditions or predispositions.
Presumably, they will need to either increase or
decrease their consumption of these components. This
information would be in public domain and freely
accessible to all, especially to health professionals
who provide dietary advice. Primary produce and
minimally processed foods would also fit this
category. Secondly, specifically manufactured
nutrigenomic foods are likely to emerge on the
market, developed in partnership with food industries
and with protected intellectual property arrangements.
These are likely to be processed foods, rather than
commodities with specific brands capturing value.
The health professional of the future would need to
have a very solid understanding of food composition
and the bioactivity of food components. They would
need to assess dietary intake with greater accuracy
and be able to prescribe diets with more
discrimination between foods and products. This
would make a call on greater use of information
technology, as food databases would need to be
continually updated and made accessible18. Food
delivery systems would need to accommodate the
discerning consumer and food labels would need to
provide the information required.
Market: Current and future
The phrase “personalised foods” may conjure
visions of nutrigenomic foods being developed by
food companies for individual consumers, but this is
unlikely due to problems of scale. Ronteltap et al.19
for example argues that “this is highly unlikely for
foods that are made using high volume production
technologies but is possible through the use of pointof-sale technologies, where (most likely) a beverage
could be prepared using a combination of ingredients
to suit an individual genotype”.

33

It is economically feasible that consumers with
specific genetic profiles that may predispose them to
particular disease or disease risk can be grouped, and
so ‘nutrigenomic foods’ could be mass customised
rather than individualised. This will depend on
growing knowledge of the prevalence of genomic
profiles, a process already begun with studies of
single nucleotide polymorphisms (SNPs), as
evidenced from a number of European Union-funded
research initiatives, including LIPGENE20 and
DIOGenes21. Product diversification may depend on
several factors, including market size and type, profit
margins, level of value capture and the level of
scientific validation required19.
Bringing foods to the marketplace is always
challenging, but in the case of functional foods,
attention is always required for establishing the
scientific evidence and then allowing for regulatory
conditions22. If nutrigenomic foods emerge as a
completely new category of foods, there may be new
needs in the areas of marketing and distribution of the
foods, which will require additional business
planning. As with the investment in any niche food,
nutrigenomic foods will need to be high value
products and extensive market research is necessary
before undertaking production23.
Consumer perceptions
Nutrigenomics is an emerging technology in the
health maintenance and promotion area, represented
by personalised food products and services. Besides
advancing the fundamental understanding of diet–
disease relationships, nutrigenomics could provide
opportunities for the development of food products or
dietary advice tailored to the nutritional needs of
specific groups of consumers, or even individuals.
Some authors have optimistically argued that these so
called “personalised foods” will shift the global food
market from a technology push into a consumer pull
system. In this situation, the consumer's preference for
optimal health is a major driver for food choice, and
food production7. In terms of ‘cost-benefit
perceptions’, the benefits of nutrigenomics are
potentially high, because it can be achieved with just
nutrition as the tool19. Health benefits relate to the
wellness, improving performance (e.g., in sports) and
ultimately longevity.
Few recent consumer studies have implicated the
possibilities of the introduction of new foods
accompanying the emerging knowledge in
nutrigenomics24,25. It is also highly likely that at least
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for preventive health effects, the total diet will remain
the major factor, so individual foods will have to
either be especially potent or play a major role in an
overall food choice pattern that can be easily matched.
For example, currently stanol enriched spreads can be
effective in dietary strategies targeting cholesterol
management, but they have to be consumed at defined
levels and the total diet should remain low in fat12. If
the food does not deliver the purported effects, the
consumer confidence will be lost, and this will affects
the whole market. Delivery of messages and delivery
systems for dietary management must be a well a
considered accompaniment.
Whatever food products are developed, there must
be some consideration for regional cuisine and food
accessibility. Presumably, staples such as rice and
bread would continue to form the backbone of various
eating patterns. Fruits and vegetables are likely to
remain significant, as more and more evidence
emerges of their potential benefits. How the new
products fit into the overall diet will be important.
Finally, taste and the social context of eating will
have an impact on the acceptability of these new
products. Eating is a deeply entrenched social and
cultural behaviour which is unlikely to be usurped by
a medicalised form of consumption. The aim for a
successful and ultimately more beneficial food supply
is to ensure it fits within the picture of acceptable and
enjoyable food consumption, made all the more
enjoyable because it is ‘good for you’.
Ethical concerns
Nutrigenomics lies in the intersection of several
fields in which ethical, legal and social issues (ELSIs)
need urgent attention, if the desirable social outcomes
are to be achieved from this promising science26-28.
Since it’s a high technology-backed discovery
science, the consumer’s expectations are very high.
The ‘biohype’ around the nutrigenomics foods and
nutrigenetics tests are imminent and unavoidable,
particularly in the early stages of evolution of a new
idea28. Practically, ‘biohype’ is already taking place
through the aggressive marketing of nutrigenomics
tests to the public, which many consider to be
premature, raising concern over ELSIs26. Five areas
have been identified by international experts26 in the
context of both basic nutrigenomics research and its
clinical and commercial uses: i) health claims benefits
arising
from
nutrigenomics,
ii)
managing
nutrigenomics information, iii) delivery methods of

nutrigenomics services, iv) nutrigenomics products,
and v) equitable accessibility to nutrigenomics. Hence
it is important to elevate the depth of debate to
understand and management of this ‘biohype’ on dietgene interactions using evidence-based research
methodologies.
Is public health going private?
During the last 50 years, public health nutrition
aims to develop “population-based strategies to
promote good health through healthy diets”30. The
effective public health nutrition interventions
generally rely on the notion of the “greatest good for
the greatest number of the population”31. But, with the
advent of nutrigenomics and nutrigenetics principles,
the future public health concept and policy need to be
redesigned. The question is whether this new
technology-driven functional foods will make an
important difference to the health of the public32.
There is a new trend in industry to privatise the public
health system.
Recently, it is reported that a large Dutch insurance
company (VGZ) has signed an agreement of
cooperation with Unilever and has described the
initiative as a “promoter of public health”. They have
promised to refund customer for three years, part of
their premiums, up to 40 Euros a year, when they buy
Unilever’s Becel pro-active products. In 2003, VGZ
spent 92 million Euros for these purposes and
following this business line, two other minor Dutch
insurance companies (IZA and IZZ) have chosen the
similar approach. This was a unique move, because
normally insurance companies do not associate with
disease prevention. The VGZ-Unilever venture seems
an offspring of a marriage between modern bioscience
and industry. There is convincing scientific evidences
on the cholesterol lowering effect of plant sterolbased products, such as margarine, milk, yoghurt etc
across the wide population, but it is still not enough at
an individual level. Nevertheless, VGZ has
announced (on its website) that it wants to take a lead
role as a “promoter of public health” by saving money
through health and conscious eating. This reflects
some of the problems associated with the health tasks
at hand and the nature of commercial relationships.
Regulation
In most of countries, food and drugs are regulated
differently. One purported difference is that while
food is a necessary requirement of survival of the
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organism, even in the absence of ill health,
pharmaceuticals contribute to survival only in a
diseased condition. For genomics-driven functional
foods, the case for using genetic information to
inform dietary advice may be stronger than that for
other foods. Traditionally, food is tested for safety,
not for efficacy, unlike drugs. Since the boundary
between food and drugs is increasingly thinned, their
regulation will, arguably, increasingly need to
consider for both safety and effectiveness23.
Under current regulatory frameworks, the rules of
the European General Food Law Regulation are
applicable to all foodstuffs. Furthermore, legislation
on dietetic foods, food supplements or novel foods,
and two proposals on nutrition and health claims and
the addition of substances to foods, may be applicable
to nutrigenomics products, depending on their nature
and their use33. Currently, claims related to reducing
risk of disease (or may be even curing disease) — the
types of claims most likely to be useful for
nutrigenomics-based products — are prohibited. Due
to the amount of regulations and procedures to be
followed, getting nutrigenomics products ready for
the market will be an expensive and time-consuming
process33. This may have large impact on the type of
companies able and willing to invest in nutrigenomics
products.
The nutrigenomics and nutrigenetics are associated
with aggressive pursuits in intellectual property
protection, though policy makers may be undecided
on how to regulate processes and products. There also
is preliminary debate on whether proprietary
discovery will impede new product development and
the dissemination of healthier foods on the widest
level in the future. In the EU, the US, Australia and
Canada, genetic testing is coming under increasing
scrutiny and governments are making efforts to
standardize regulations. However, nutrigenetics tests
are considered “lifestyle” tests, largely because they
do not make clinical claims. The EU considers most
genetic tests low risk and thus exempt from
independent pre-market review. In Canada and
Australia, there are even fewer controls. Currently,
nutrigenetics tests are reviewed for neither analytical
nor clinical accuracy. Very recently, the European
Nutrigenomics Organisation34 (NuGo) has published
the framework to advise scientists in some of the
ethical issues surround nutrigenomics, such as storage
of genetic data, with the long-term aim to produce a
European standard. The guidelines are not a legal
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document and that the ethical approval for
nutrigenomics research will depend on the legal
standards developed in individual member states.
Conclusion
Nutrigenomics is a potentially promising
development in emerging functional food and
nutraceutical research. The value add now moves on
to not just components with newly discovered
functional properties, but also how these functional
properties may interact with the genetic environment
of the consumer. However, it is still in its infancy, and
there are quite some uncertainties about its further
development, both from technological and societal
acceptance point of view. Healthcare practice and
food product development will move on regardless
and it is the partnership of science and practice that
will enable a smooth uptake and translation of new
knowledge in the field as it emerges. Steps in this
direction, however, must be taken with caution and
great care. There are ethical issues to consider, in
terms of consumer confidentiality and rights to be
fully informed. It will be increasingly necessary to
communicate the extent of the lack of knowledge, as
it is the extent of knowledge in the area to maintain
trust, build effective partnerships (including with
consumers) and, and most importantly, to do no harm.
The potential, however, is almost utopian, as we move
toward understanding the genetic details behind
human biology and the way in which the consumption
of food, one of life’s simplest and great pleasures can
have such an enormous impact on life itself.
Future development in the field of nutrigenomics
undoubtedly will place its seemingly huge potential in
better perspective. From the scientific responsibility
point of view, one hopes that the new perspectives to
be gained and progress to be made in this field will be
so managed as to take the public at large on board, if
we are to avoid another nutrition education disaster of
the genetically modified organism (GMO) type and
dimension.
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